A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 2/3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma
Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 19 Apr 2017
At a glance
- Drugs Ibrutinib (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms RESOLVE
- Sponsors Pharmacyclics
- 04 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 17 Jan 2017 Planned number of patients changed from 326 to 426.
- 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology